Alaunos Therapeutics Inc
TCRT
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.69M
Close$
$0.53
64.9% downside
Current Fair Value
64.9% downsideOvervalued by 64.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.69 Million |
|---|---|
| Enterprise Value | $3.56 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.2 |
| Beta | -0.97 |
| Outstanding Shares | 2,431,695 |
Return
| Return on Equity | -615.03% |
|---|---|
| Return on Assets | -264.51% |
| Return on Invested Capital | -625.31% |
Valuation & Multiples
| P/E Ratio | -0.77 |
|---|---|
| PEG | 8.22 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1187.88 |
| Enterprise Value to EBIT | -0.87 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-15.75
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.72%▼ 2.75% |
|---|---|
| Total Invested | $204,507▼ 43.28% |
| Investors Holding | 30▲ 1.00% |
ESG Score
No data
About Alaunos Therapeutics Inc
105 employeesZiopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled int...